



NDA 50-680/S-010
NDA 50-767/S-011

SUPPLEMENT APPROVAL

Pharmacia and Upjohn Company
Attention: Mikhail Abarshalin
Senior Manager, Worldwide Safety and Regulatory
235 East 42nd Street
New York, NY 10017

Dear Mr. Abarshalin:

Please refer to your Supplemental New Drug Applications (sNDAs) dated October 15, 2013, received October 15, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for CLEOCIN HCl (clindamycin hydrochloride, USP) Vaginal Cream (NDA 50-680) and CLEOCIN PHOSPHATE (clindamycin phosphate vaginal suppositories) Vaginal Ovules (NDA 50-767).

We acknowledge receipt of your amendments dated November 12, 2013, and March 27, 2014.

These "Prior Approval" supplemental new drug applications provide for:

- (1) The addition of information to the Carcinogenesis, Mutagenesis, Impairment of Fertility and Pregnancy: Teratogenic effects subsections regarding reproductive toxicity studies in rats and mice as well as clarification to language about use of clindamycin in pregnancy and by nursing mothers.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the

addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 050680/S-10
NDA 050767/S-11
Page 3

If you have any questions, call Jane A. Dean, RN, MSN, Regulatory Health Project Manager, at (301) 796-1202.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
05/09/2014